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Background:  Cardiac involvement may occur in up to 50% of patients with amyloidosis and portends an adverse prognosis. Non-invasive 
diagnosis, particularly in the setting of chronic renal failure (CRF), remains imprecise due echocardiographic changes from concomitant pathology. 
CMR with typical late gadolinium enhancement (LGE) is a highly specific method for diagnosis of cardiac amyloidosis in patients without CRF. 
Although nephrogenic systemic fibrosis (NSF) has been reported in patients with CRF after gadolinium, the incidence is rare. We sought to determine 
the incremental diagnostic value of LGE CMR in patients with systemic amyloidosis/light chain deposition disease (LCDD) and CRF in whom 
echocardiography and clinical signs were equivocal.
Methods:  Consecutive patients with systemic amyloidosis or LCDD, with uncertain cardiac involvement by echocardiography, referred for CMR-LGE 
were prospectively studied. LGE-CMR at 1.5T (Siemens, Avanto) was performed after administration of 0.1 mmol/kg of Gadovist. The presence of 
midwall LGE was determined by a blinded specialist. Same-day dialysis was prescribed.
Results:  Twenty patients (14 male (70%), age 65±13, CKD stage 5: 15 (75%), Stage 4: 5 (25%), Haemodialysis: 14 (70%), Subtypes: AL 9 (45%), 
LCDD 6 (30%), Other 5 (25%)) were studied. LGE typical for amyloidosis (defined as circumferential subendocardial or transmural enhancement) 
was present in 7 (35%), an atypical pattern in 9 (45%), and no LGE in 4 (20%). Importantly, there was no significant difference between typical LGE 
compared with no or atypical LGE in LV wall thickness, EF%, LA area, TDI septal or lateral, E’, E/E’, E/A, IVRT (all p>0.05) or the echo-cardiologist’s 
impression of diastolic dysfunction (Chi2 1.03, p=0.79). No adverse effects were observed.
Conclusion:  LGE-CMR provides incremental diagnostic information in patients with CRF and amyloidosis, affording diagnosis of cardiac 
involvement in 35% of patients with equivocal echocardiographic and clinical signs. This valuable diagnostic and prognostic information in 
amyloidosis (especially AL) needs to be weighed against the potential risk of rare but serious complication of NSF in this cohort.
